CSL: An Aussie success story

CSL is outperforming the market and expanding its reach

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO) up 10.5% this year, blood plasma therapeutics group CSL Limited (ASX: CSL) has outperformed the market by an impressive 37%.

I'm certainly not the first to say it, but CSL is a truly great Australian success story. From humble beginnings, the government-owned Commonwealth Serum Laboratories has grown into a world leader in the development and manufacture of plasma-derived therapies that treat disorders such as haemophilia and produce vaccines that prevent influenza and cervical cancer.

With operations in Europe, USA, and Australia, CSL sells into all major markets, including emerging markets such as China where it is the leading supplier of albumin, a critical component of blood plasma. As a global business, CSL earns the majority of its money in foreign currency, and therefore the reported results are exposed to fluctuations in exchange rates. As is becoming common practice with Australian domiciled multi-nationals, CSL will begin reporting in US dollars for the 2013 financial year to counter this issue.

CSL also announced in early August that long-serving CEO Dr Brian McNamee would be retiring at the end of the 2013 financial year. McNamee has played a pivotal role in the success of CSL but thankfully the company has in place a depth of talent and a planned transition to the incoming CEO, Mr Paul Perreault, who is an experienced senior member of the management team.

There are a number of catalysts that have likely helped the re-rating of CSL this year. Capital management initiatives such as the continual buying back of shares are one. With the latest $900 million buyback 77% complete, the full-year results presentation provided the opportunity to announce that a further $900 million buyback was being considered.

However, the primary catalyst for the rising share price has most likely simply been the stellar results CSL continues to produce.

Foolish takeaway

CSL is an example of the returns an investor can enjoy buying a great business at a reasonable price. Remaining alert for any short-term issues which can lead to a temporary drop in share price will help Fools seize the opportunity to buy into wide-moat businesses such as CSL.

CSL shows that investing in a successful biotech company can do wonders for your wealth. It is always difficult to pick the winners early.

For two more up-and-coming biotechs, check out our brand-new report, "Top 2 Biotechs to Buy Now." These two companies — each with potential blockbuster drugs in the pipeline — could create untold wealth for early investors. Will you be one of them? Click here for this brand-new FREE report.

More reading:

Motley Fool contributor Tim McArthur doesn't own any of the stocks mentioned. The Motley Fool's purpose is to help the world invest, better. Take Stock is The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. Click here now to request your free subscription. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »